Wire · opportunities
Lakewood-Amedex Announces IRB Approval and Clinical Site Readiness to Initiate Phase ...
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 21 September 2026 · Fusion42 review
Lakewood-Amedex Biotherapeutics has obtained IRB approvals and clinical site readiness to start its Phase 2a trial of Nu-3, a novel antimicrobial gel targeting mildly infected diabetic foot ulcers. The trial aims to evaluate safety and efficacy, addressing drug-resistant wound infections with a unique mechanism to evade antibiotic resistance.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
Your antimicrobial biotech now has a clear path to validate a product addressing resistant infections after IRB approval. Use this momentum this week to engage with clinical sites and potential partners positioned for tackling antibiotic resistance.
◆ Coverage
1 source · 21 Sep 2026
◆ Related on Wire
◆ Topics